Botryllamide C | 163564-66-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: Botryllamide C
• 英文别名: (Z)-N-[(E)-2-(3-bromo-4-methoxyphenyl)ethenyl]-3-(4-hydroxyphenyl)-2-methoxyprop-2-enamide
• CAS: 163564-66-7
• 化学式: C₁₉H₁₈BrNO₄
• 分子量: 404.26
• InChiKey: UCXFHNQSLPZQNU-IGZKKZBOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (Z)-3-(4-hydroxyphenyl)-2-methoxyacrylamide 、 2-bromo-4-ethynyl-1-methoxybenzene 在 [bis(2-methylallyl)cycloocta-1,5-diene]ruthenium(II) 、 1,4-双(二环己基膦)丁烷 、 水 、 ytterbium(III) triflate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 以88%的产率得到Botryllamide C
  参考文献：
  名称：

  钌催化炔烃加氢酰胺化合成葡萄酰胺和兰酰胺

  摘要：

  炔烃的钌催化加氢酰胺化允许简洁的合成进入 E-和 Z-配置的烯酰胺天然产物。这通过从简单的市售前体以 1-3 个步骤合成葡萄酰胺 C 和 E、兰胺酰胺 A 和 B 以及兰酰胺 I 以及 57-98% 的产率得到了证明。

  DOI：

  10.1055/s-0029-1219961

文献信息

• METHOD OF INHIBITING ABCG2 AND OTHER TREATMENT METHODS
  申请人：Henrich Curtis J.

  公开号：US20100317732A1

  公开（公告）日：2010-12-16

  Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.
• US8470888B2
  申请人：——

  公开号：US8470888B2

  公开（公告）日：2013-06-25
• US9314448B2
  申请人：——

  公开号：US9314448B2

  公开（公告）日：2016-04-19
• [EN] METHOD OF INHIBITING ABCG2 AND OTHER TREATMENT METHODS<br/>[FR] PROCÉDÉ D'INHIBITION D'ABCG2, ET AUTRES PROCÉDÉS DE TRAITEMENT
  申请人：US HEALTH

  公开号：WO2009088831A2

  公开（公告）日：2009-07-16

  Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.
• Synthesis of Botryllamides and Lansiumamides via Ruthenium-Catalyzed Hydroamidation of Alkynes
  作者：Lukas Gooßen、Mathieu Blanchot、Matthias Arndt、Kifah Salih

  DOI：10.1055/s-0029-1219961

  日期：2010.7

  Ruthenium-catalyzed hydroamidations of alkynes allow a concise synthetic entry to both E- and Z-configured enamide natural products. This was demonstrated by the synthesis of botryllamides C and E, lansiumamides A and B, and lansamide I in 1-3 steps and 57-98% yield from simple, commercially available precursors.

  炔烃的钌催化加氢酰胺化允许简洁的合成进入 E-和 Z-配置的烯酰胺天然产物。这通过从简单的市售前体以 1-3 个步骤合成葡萄酰胺 C 和 E、兰胺酰胺 A 和 B 以及兰酰胺 I 以及 57-98% 的产率得到了证明。